Clinical Trials on Germ Cells Tumors in Belgium

Total 1585 results

AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Oncopeptides AB

Terminated

A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide (OCEAN)

Multiple Myeloma

United States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
pharmaand GmbH

Completed

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma (PANORAMA_3)

Multiple Myeloma

Canada, Spain, United States, Czechia, Turkey, France, Sweden, Korea, Republic of, Thailand, Belgium, Greece, Germany, Hungary, Russian Federation, Italy, Poland, Australia, Lebanon, Portugal, Norway, Brazil, Netherlands
Bristol-Myers Squibb
Pfizer

Completed

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

Lymphoma | Acute Lymphoblastic Leukemia

United States, Canada, Mexico, Belgium, Russian Federation, Hungary, Korea, Republic of, Australia, Puerto Rico, Czechia, New Zealand, Poland
Mersana Therapeutics
IQVIA Biotech; PSI CRO

Recruiting

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

Platinum Resistant Ovarian Cancer | Non Small Cell Lung Cancer Metastatic

United States, Spain, United Kingdom, Australia, France, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hungary, Italy, Lithuania, New Zealand, Norway, Poland, Sweden
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Millennium Pharmaceuticals, Inc.

Completed

A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Multiple Myeloma

United States, United Kingdom, Canada, Israel, France, Austria, Belgium, Germany, Ireland, Italy, Netherlands, Spain, Sweden
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Chronic Myeloid Leukemia | Blast Crisis

Netherlands, United States, Italy, Austria, Canada, France, Germany, Singapore, Taiwan, United Kingdom, Australia, Korea, Republic of, Philippines, Sweden, Finland, Israel, Belgium, Denmark, Norway, Switzerland
AbbVie

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)

Giant Cell Arteritis (GCA)

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Portugal, Romania, Russian Federation, Spain, Sweden, Switzerland, United...
Amgen

Completed

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Leukemia, Acute Lymphoblastic

Italy, United Kingdom, Belgium, Mexico, Germany, Russian Federation, Turkey, Spain, Australia, Poland, Austria, Czechia, France, Portugal, Israel, Denmark, Brazil, Romania, Sweden, Switzerland, Norway, Netherlands, Argentina, Greece
Intergroupe Francophone du Myelome
Janssen Research & Development, LLC; HOVON - Dutch Haemato-Oncology Association

Active, not recruiting

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma (Cassiopeia)

Multiple Myeloma

Netherlands, France, Belgium
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

Carcinoma, Non-Small-Cell Lung

Canada, Germany, Italy, China, Belgium, United States, Taiwan, Israel, United Kingdom, Korea, Republic of, Sweden, Japan, Poland, Malaysia, Netherlands, Spain, Turkey, France, India, Mexico, Argentina, Brazil, Portugal, Russian Federation and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Germany, Japan, China, Israel, Belgium, Italy, France, Taiwan, Thailand, Korea, Republic of, Malaysia, Spain, Hungary, Turkey, Portugal, India, Brazil, Poland, Australia, Russian Federation, Mexico, Puerto Rico, U... and more
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Multiple Myeloma

United States, Korea, Republic of, Denmark, Czechia, Israel, Switzerland, Belgium, United Kingdom, Japan, Argentina, Sweden, Canada, Spain, Germany, Netherlands, France, Brazil, Greece, Poland, Ireland, Hungary, Portugal, Australia, F... and more
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
Sanofi
Regeneron Pharmaceuticals

Terminated

Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA

Giant Cell Arteritis

Argentina, Estonia, France, United States, Australia, Belgium, Canada, Croatia, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Portugal, Russian Federation, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

Carcinoma, Non-Small-Cell Lung

United States, France, Canada, China, Israel, Belgium, United Kingdom, Italy, Argentina, Japan, Taiwan, Thailand, Korea, Republic of, Malaysia, Poland, Australia, Spain, Netherlands, Hungary, Turkey, Germany, India, Brazil, Russian Federation and more
Pfizer

Terminated

Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Australia, United States, Hungary, Germany, Italy, Korea, Republic of, Spain, Sweden, Mexico, South Africa, Taiwan, Belgium, Canada, China, Cyprus, Czech Republic, France, Greece, Hong Kong, India, Israel, Netherlands, Poland, Portugal, Switzerlan... and more
Boehringer Ingelheim

Completed

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain, Germany, China, Israel, Denmark, Belgium, Switzerland, Croatia, Poland, Romania, South Africa, Czechia, Greece, Portugal, United Kingdom, India, Italy, Austria, Belarus, Ukraine, Russian Federation, France, Bulgaria, Georgia, Korea... and more
AstraZeneca

Active, not recruiting

First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

NSCLC

France, Germany, Italy, Netherlands, United Kingdom, Belgium, Israel, Australia, Switzerland, Norway
AstraZeneca

Completed

Epidemiological Study to Describe NSCLC Clinical Management Patterns in Europe. Lung-EPICLIN (EPICLIN)

NSCLC

France, Italy, Spain, Turkey, Belgium, Portugal, Greece, Germany
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)

Carcinoma, Non-Small-Cell Lung

United States, Spain, France, Belgium, Australia, Germany, Argentina, Japan, Brazil, Italy, Singapore, Russian Federation, Taiwan, Netherlands, Peru, Chile, Latvia, Ukraine, Mexico, Lithuania, Slovakia, Bulgaria, Portugal, Austria, Swit... and more
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Takeda

Completed

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Multiple Myeloma

United States, Spain, United Kingdom, Belgium, Taiwan, Italy, Israel, China, Turkey, Germany, Greece, Mexico, Colombia, France, Brazil
Stichting Hemato-Oncologie voor Volwassenen Nederland
European Myeloma Network; Gruppo Italiano Malattie EMatologiche dell'Adulto; DSMM... and other collaborators

Active, not recruiting

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma (HO95)

Multiple Myeloma

Sweden, Norway, Italy, Netherlands, Belgium, Switzerland, Australia, Denmark, Finland, Czechia, Turkey, Austria, Luxembourg, Hungary, Greece, Portugal
Amgen

Completed

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Relapsed Multiple Myeloma

United States, Canada, United Kingdom, France, Belgium, Austria, Spain, Israel, Italy, Bulgaria, Czechia, Germany, Greece, Hungary, Netherlands, Poland, Romania, Russian Federation, Serbia, Sweden
Janssen Research & Development, LLC

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Multiple Myeloma

Australia, France, Poland, United Kingdom, United States, Spain, Israel, Portugal, South Africa, Canada, Netherlands, Belgium, Singapore, Russian Federation, Czech Republic, Argentina, Austria
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)

Lymphoblastic Lymphoma, Childhood

Spain, Austria, Denmark, Finland, Germany, Belgium, Switzerland, China, Czechia, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Taiwan, China, Canada, Spain, Japan, Germany, United Kingdom, Brazil, India, Korea, Republic of, Australia, Italy, Norway, Israel, Greece, Turkey, Netherlands, Austria, Belgium, Hong Kong, Poland, Puerto Rico, Russian... and more
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Taiwan, Belgium, Denmark, Switzerland, Argentina, Israel, Italy, Croatia, United Kingdom, Korea, Republic of, Russian Federation, Slovakia, Japan, Bulgaria, Poland, Hungary, Australia, Turkey, Peru, Chile, Mexico, Czech... and more
GlaxoSmithKline

Terminated

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Giant Cell Arteritis

United States, Spain, Germany, Italy, Belgium, France, Netherlands, Australia, United Kingdom, Hungary, Poland, Bulgaria, New Zealand
Pfizer

Active, not recruiting

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Carcinoma, Non-Small-Cell Lung

Canada, Spain, United States, China, Korea, Republic of, United Kingdom, France, Czechia, Japan, Singapore, Taiwan, Australia, Netherlands, India, Turkey, Hong Kong, Argentina, Belgium, Germany, Italy, Mexico, Poland, Russian Federation
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Multiple Myeloma

Australia, Poland, United Kingdom, United States, Belgium, Germany, Spain, Argentina, Portugal, Bulgaria, Romania, Serbia, Turkey, Ukraine, Japan, Greece, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia, Croatia, Ge... and more
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Netherlands, Germany
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Denmark, Greece, Slovakia
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Israel, United Kingdom, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, France, Turkey, Russian Federation, Greece, Australia, Puerto Rico
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Karyopharm Therapeutics Inc

Active, not recruiting

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)

Multiple Myeloma

United States, United Kingdom, Australia, Israel, Canada, Belgium, Austria, Czechia, Serbia, India, France, Italy, Russian Federation, Bulgaria, Germany, Greece, Hungary, Poland, Romania, Spain, Ukraine
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States, France, Norway, Spain, Israel, United Kingdom, Italy, Australia, Germany, Greece, Canada, Czechia, Turkey, Russian Federation, Denmark, Sweden, Belgium, Netherlands
Novartis Pharmaceuticals

Completed

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Carcinoma, Non-Small-Cell Lung

Italy, Spain, Germany, Japan, Taiwan, Belgium, Netherlands, Singapore, Argentina, France, Israel, Sweden, Korea, Republic of, Lebanon, United Kingdom, United States, Austria, Mexico, Norway, Russian Federation

Clinical Trials on Germ Cells Tumors in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations